Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 12—December 2008

CME ACTIVITY - Research

Clinical Characteristics and Molecular Subtyping of Vibrio vulnificus Illnesses, Israel

Ronit Zaidenstein, Chantal Sadik, Larisa Lerner, Lea Valinsky, June Kopelowitz, Ruth Yishai, Vered Agmon, Michele B. Parsons, Cheryl Bopp, and Miriam WeinbergerComments to Author 
Author affiliations: Assaf Harofeh Medical Center, Zerifin, Israel (R. Zaidenstein, M. Weinberger); Israel Ministry of Health, Jerusalem, Israel (C. Sadik, L. Lerner, L. Valinsky, J. Kopelowitz, R. Yishai, V. Agmon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Parsons, C. Bopp); Tel Aviv University, Ramat Aviv, Israel (M. Weinberger)

Main Article

Figure 1

Figure 1 - PCR restriction fragment length polymorphism of Vibrio vulnificus cytotoxin gene vvhA. A) PCR amplicon of vvhA gene restriction digested with B) PstI or C) KpnI. Gel shows molecular size standards (M) and V. vulnificus biotype 3 (lanes 1–3) and biotype 1 (lane 4).

Figure 1. PCR restriction fragment length polymorphism of Vibrio vulnificus cytotoxin gene vvhA. A) PCR amplicon of vvhA gene restriction digested with B) PstI or C) KpnI. Gel shows molecular size standards (M) and V. vulnificus biotype 3 (lanes 1–3) and biotype 1 (lane 4).

Main Article

TOP